Latest 4Dmedical (ASX:4DX) News

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

4DMedical launches the CLEAR clinical evidence program to accelerate adoption of its CT:VQ™ imaging technology in the US acute pulmonary embolism market, aiming to expand its addressable market to US$3 billion.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

Battery tech, biotech and balance-sheet repair drove the biggest gains this week, while guidance cuts and weak post-halt trading hurt several names. Deal-making and fresh equity funding stayed busy, especially in rare earths, defence and gold.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

4DMedical’s CT:VQ™ technology has been clinically validated in a top respiratory journal, showing a leap in patient response rates for lung volume reduction surgery from 46% to 76%, promising improved outcomes and hospital efficiencies.

Small caps drove the biggest moves, with Alvo Minerals surging, Klevo extending a payments-fuelled rally, and FBR jumping on fresh contract news. At the larger end, takeover bids, mine funding deals and a strong Liontown update kept resources and corporate activity at the centre of trading.

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Speculative resources names drove the biggest moves this week, with Patriot Resources, Brazilian Critical Minerals and Rent.com.au leading the gainers. At the other end, Qoria, SQX Resources and 4DMedical fell hard as capital raisings, weak follow-through and post-gap selling hit sentiment.